Edgemoor Investment Advisors, Inc. Gilead Sciences, Inc. Transaction History

Edgemoor Investment Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$62.32 - $89.47 $225,473 - $323,702	3,618 New	3,618 $310,000
Q4 2018 Jan 31, 2019	SELL	$60.54 - $79.0 $183,738 - $239,765	-3,035 Closed	0 $0
Q3 2018 Oct 26, 2018	SELL	$71.28 - $78.92 $90,169 - $99,833	-1,265 Reduced 29.42%	3,035 $234,000
Q2 2018 Aug 02, 2018	SELL	$64.88 - $75.68 $8.18 Million - $9.54 Million	-126,027 Reduced 96.7%	4,300 $305,000
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $149,759 - $182,572	-2,056 Reduced 1.55%	130,327 $9.83 Million
Q4 2017 Feb 07, 2018	SELL	$71.15 - $83.52 $377,948 - $443,658	-5,312 Reduced 3.86%	132,383 $10.6 Million
Q3 2017 Nov 09, 2017	BUY	$72.11 - $85.47 $9.93 Million - $11.8 Million	137,695	137,695 $11.2 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Edgemoor Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Edgemoor Investment Advisors, Inc. with notifications on news.